Cargando…

LPAR1 regulates the development of intratumoral heterogeneity in ovarian serous cystadenocarcinoma by activating the PI3K/AKT signaling pathway

BACKGROUND: To explore the role of lysophosphatidic acid receptor 1 (LPAR1) and its correlation with the PI3K/AKT pathway in the development of intratumoral heterogeneity (ITH) in human ovarian serous cystadenocarcinoma (OSC). METHODS: Immunohistochemical staining was performed to detect LPAR1 expre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, Ran, Cao, Guangming, Bai, Huimin, Zhang, Zhenyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664705/ https://www.ncbi.nlm.nih.gov/pubmed/31384176 http://dx.doi.org/10.1186/s12935-019-0920-0

Ejemplares similares

Comprehensive analysis of LDHAP5 pseudogene expression and potential pathogenesis in ovarian serous cystadenocarcinoma
por: Lin, Shitong, et al.
Publicado: (2020)

Comprehensive analysis of the expression of sodium/potassium-ATPase α subunits and prognosis of ovarian serous cystadenocarcinoma
por: Huang, Wei, et al.
Publicado: (2020)

Gastric metastasis of ovarian serous cystadenocarcinoma
por: Yang, Shiqiang
Publicado: (2018)

ZEB1-AS1/miR-133a-3p/LPAR3/EGFR axis promotes the progression of thyroid cancer by regulating PI3K/AKT/mTOR pathway
por: Xia, Wu, et al.
Publicado: (2020)

Serous cystadenocarcinoma of the spleen
por: Chou, Chung Kuao, et al.
Publicado: (2017)

Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells
por: Hiss, Donavon C, et al.
Publicado: (2007)

Mining TCGA database for gene expression in ovarian serous cystadenocarcinoma microenvironment
por: Xu, Youzheng, et al.
Publicado: (2021)

Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas
por: Tone, Alicia A, et al.
Publicado: (2014)

High-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation
por: Bourgeois, Danielle L., et al.
Publicado: (2015)

Increased Expression of LYNX1 in Ovarian Serous Cystadenocarcinoma Predicts Poor Prognosis
por: Liu, Hui, et al.
Publicado: (2020)

An Immune-Related Gene-Based Signature as Prognostic Tool in Ovarian Serous Cystadenocarcinoma
por: Shi, Fengjuan, et al.
Publicado: (2021)

Gene Expression Subtyping Reveals Immune alterations:TCGA Database for Prognosis in Ovarian Serous Cystadenocarcinoma
por: Feng, Chunxia, et al.
Publicado: (2021)

PGM1 suppresses colorectal cancer cell migration and invasion by regulating the PI3K/AKT pathway
por: Zheng, Zhewen, et al.
Publicado: (2022)

YWHAE as an HE4 interacting protein can influence the malignant behaviour of ovarian cancer by regulating the PI3K/AKT and MAPK pathways
por: Li, Xiao, et al.
Publicado: (2021)

Midkine promotes glioblastoma progression via PI3K-Akt signaling
por: Hu, Beiquan, et al.
Publicado: (2021)

Estimation of Prognostic Marker Genes by Public Microarray Data in Patients with Ovarian Serous Cystadenocarcinoma
por: Yang, San-Duk, et al.
Publicado: (2016)

A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma
por: Liu, Li-Wei, et al.
Publicado: (2016)

Expression of Yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma
por: Cho, Sang Yeon, et al.
Publicado: (2017)

Development and Validation of an RNA-Binding Protein-Based Prognostic Model for Ovarian Serous Cystadenocarcinoma
por: He, Yunan, et al.
Publicado: (2020)

Assessment of Significant Pathway Signaling and Prognostic Value of GNG11 in Ovarian Serous Cystadenocarcinoma
por: Jiang, Ming-Min, et al.
Publicado: (2021)

TRPs in Ovarian Serous Cystadenocarcinoma: The Expression Patterns, Prognostic Roles, and Potential Therapeutic Targets
por: Zhang, Cheng, et al.
Publicado: (2022)

Genome-Wide Identification and Validation of Gene Expression Biomarkers in the Diagnosis of Ovarian Serous Cystadenocarcinoma
por: Zalfa, Francesca, et al.
Publicado: (2022)

Stem Cell-Associated Signatures Help to Predict Diagnosis and Prognosis in Ovarian Serous Cystadenocarcinoma
por: Li, Li, et al.
Publicado: (2023)

Periostin promotes the proliferation and metastasis of osteosarcoma by increasing cell survival and activates the PI3K/Akt pathway
por: Xu, Chaojian, et al.
Publicado: (2022)

Pancreatic serous cystadenocarcinoma with invasive growth into the colon and spleen
por: Cho, Wontae, et al.
Publicado: (2011)

Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma
por: Shi, Zhiwen, et al.
Publicado: (2021)

A novel ferroptosis related gene signature is associated with prognosis in patients with ovarian serous cystadenocarcinoma
por: Yu, Zhixiang, et al.
Publicado: (2021)

KRT19 is a Promising Prognostic Biomarker and Associates with Immune Infiltrates in Serous Ovarian Cystadenocarcinoma
por: Sun, Zhe, et al.
Publicado: (2023)

Intratumoral Genomic Heterogeneity May Hinder Precision Medicine Strategies in Patients with Serous Ovarian Carcinoma
por: Nakamura, Kohei, et al.
Publicado: (2020)

Pancreatic Serous Cystadenocarcinoma: A Case Report and Review of the Literature
por: King, Jonathan C., et al.
Publicado: (2009)

Serous cystadenocarcinoma of the pancreas: report of a case and management reflections
por: Bramis, K, et al.
Publicado: (2012)

Hepatic resection of metastatic tumor from serous cystadenocarcinoma of the ovary.
por: Lee, Jong Hoon, et al.
Publicado: (2002)

Low expression of acyl-CoA thioesterase 13 is associated with poor prognosis in ovarian serous cystadenocarcinoma
por: Lv, Xiaofeng, et al.
Publicado: (2023)

PI3-K/Akt pathway contributes to IL-6-dependent growth of 7TD1 cells
por: Zhang, JiYan, et al.
Publicado: (2003)

Celecoxib enhances anticancer effect of cisplatin and induces anoikis in osteosarcoma via PI3K/Akt pathway
por: Liu, Bing, et al.
Publicado: (2017)

Effect of nicastrin on hepatocellular carcinoma proliferation and apoptosis through PI3K/AKT signalling pathway modulation
por: Wang, Xicheng, et al.
Publicado: (2020)

Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer
por: Chan, Karen K. L., et al.
Publicado: (2018)

Activation of EGFR-PI3K-AKT signaling is required for Mycoplasma hyorhinis-promoted gastric cancer cell migration
por: Duan, Hongying, et al.
Publicado: (2014)

CMTM5 is downregulated and suppresses tumour growth in hepatocellular carcinoma through regulating PI3K-AKT signalling
por: Xu, Gang, et al.
Publicado: (2017)

SKA3 promotes cell proliferation and migration in cervical cancer by activating the PI3K/Akt signaling pathway
por: Hu, Rong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mlpqlvn15nu3spidvc3rbflae4